Transcription
Welcome back. In this lecture, we are going to talk about depressive disorders.
I would like to begin by introducing you to the nature of mood, or affective, disorders. Mood disorders encompass a range of conditions characterized by an abnormality in mood. But it is crucial to understand their differences to avoid confusion. Non-psychotic mood disorders, like depressive disorder (in older terms, unipolar depression), involve persistent feelings of sadness without psychotic features. Hypomania, a milder form of mania, may occur on its own or as part of bipolar disorder (also called manic-depressive psychosis), which causes swings between depression and elevated mood (mania or elation). Psychotic mood disorders, such as psychotic depression, include depressive symptoms accompanied by psychosis. While both bipolar and unipolar disorders impact mood, their etiology, impact, treatment, and prognosis differ significantly. It's this distinction in symptoms and underlying mechanism that often leads to their misclassification as a single disorder when, in fact, they are distinct conditions requiring tailored approaches.
In this lecture, we're going to focus on depressive disorders, or unipolar depression. We will introduce their etiology, their presentation, and their prevalence, and treatment for you to understand more. Now please look at the ICD-10 and DSM-5 criteria.
Let's break down the criteria for major depressive disorder as it's outlined in the DSM-5. Think of it like a checklist. If someone has been experiencing at least five out of nine specific symptoms over the past two weeks, and one of these symptoms is either a really low mood or a loss of interest and pleasure in things they usually enjoy, then they might be going through a major depressive episode, similar to what's described in the ICD-10.
Now, one of the big changes in the DSM-5 is how it handles grief. In the past, if someone was really down after losing a loved one, they wouldn't be diagnosed with depression right away. There was a kind of grace period called the bereavement exclusion. But the DSM-5 got rid of that, and it stirred up quite the debate. Some folks think that this change means normal grief may be mistaken for depression, leading to people taking medication they don't need. But here's the other side of the coin: grief doesn't protect someone from getting depression; in fact, losing someone close to you can really trigger it. The tricky part is figuring out when someone's just going through the normal grieving process and when it's actually a major depressive episode. Because, let's face it, missing the signs of severe depression is risky business; it can lead to some serious consequences, including suicide. So, although it's a tough topic, doing away with the bereavement exclusion in the DSM-5 makes it possible to keep a closer eye on people in mourning, just in case their grief turns into something more serious. It's important to remember that recognizing the signs of depression in someone who's grieving doesn't automatically mean they should start popping pills. It's all about making smart, careful choices to help them through a tough time.
In more casual terms, when we're talking about major depressive disorder as defined by the DSM-5, we're really talking about how intense and how often someone's periods of depression occur. Now imagine someone's mood takes a big dive and stays down for at least two weeks; that's what we call a depressive episode. If they've never had super high or manic times, then we stick with the label major depressive disorder. And it can be a one-time thing or something that happens again and again.
Now, the ICD, that's another handbook for understanding mental health, breaks down depression into subtypes like mild, moderate, severe, and even notes if someone's getting better (in remission). With severe depression, we have to pay extra attention because sometimes it comes with those really intense symptoms like psychosis, but that's not so common. Still, we need to keep our eyes peeled because when psychosis shows up, it changes the game in terms of treatment and management. For milder forms of depression, folks might have trouble sleeping, feel restless at night, or wake up really early. Unlike the most severe types, they usually don't have those physical signs like not eating much, losing weight, or losing interest in, you know, bedroom activities. Many times these milder blues are linked to tough times in someone's life and get better when things look up or when they adjust to the new normal. But sometimes it sticks around, and it's still rough on them, even if they're not feeling worse over time.
Now, in terms of risk factors for major depressive disorder, it's a mixed bag. But there are also these less obvious symptoms that aren't usually the main thing in severe cases. We used to call them neurotic things: like feeling really anxious, having specific fears or phobias, maybe being caught up in some thoughts over and over, or feeling disconnected from reality on occasion.
In terms of prevalence, how common is it? If you can see the number—the 12-month prevalence of major depression—what does it mean? The numbers tell us that in any given year, about 2 to 5% of people may experience it. When you look at a person's whole life, the chance goes up, with 10 to 20% of folks having a run-in with major depression at some point. Now, when are you most likely to see this start? The age when it's most common for depression to first show up is in a person's mid-20s. And here's a fact that stands out: women are about twice as likely as men to experience it. Does it mean men are mostly in the clear when it comes to mood disorders? Not exactly. It could be that men are less likely to seek help, or that their depression shows up in different ways, like anger or substance misuse—what some people sometimes call masked depression.
Speaking of life's hard knocks and depression, it's more common among people who are out of work or who've gone through a divorce. And it doesn't often come alone. A lot of people who deal with depression are also tackling anxiety disorders or maybe using alcohol or drugs in a way that is not healthy, which can sometimes hide their depression symptoms.
When we delve into the causes of mood disorders, genetics play a big part, especially in the case of bipolar disorders. Studies involving twins and adoption have highlighted that genes are a significant factor. If one identical twin has bipolar disorder, the chances the other twin will also have it are much higher compared to fraternal twins, which points to the role of heredity. For unipolar depression, the genetic link is there, but it's not as strong as it is for bipolar disorder. Then there is the environment you grow up in, especially early on. John Bowlby's pioneering work talked about maternal deprivation and how critical the early bond between a child and their caregiver is. If the bond is disrupted, it can set the stage for mood disorders later in life. More broadly, any form of childhood adversity and abuse can increase the risk of depression. If a kid grows up with a parent who's depressed, they may learn to see the world in a more negative light. This is what we mean by social learning: children often pick up and may internalize the behaviors and attitudes of their parents. Personality also comes into play. The inherent temperament a person is born with can predispose them to react to life in certain ways that might contribute to depression. And then there's cognitive style—basically, it's how we think about and interpret what happens to us. Aaron Beck, a big name in psychology, developed a cognitive model of depression, which suggests that people with depression often have patterns of negative thinking that can keep the depression going. It's like a cycle of gloomy thoughts that reinforce and amplify the low mood.
What about other factors? In terms of psychological factors, significant life events such as job loss, the death of a loved one, or a major life transition can act as catalysts for depression. These events can create significant stress, and if coping mechanisms are inadequate, may lead to an individual experiencing depressive symptoms. In terms of learned helplessness, it is a concept introduced by Martin Seligman. Learned helplessness describes a condition in which a person has learned to behave helplessly, failing to respond even though there are opportunities to avoid unpleasant circumstances or gain positive rewards. This behavior stems from the perceived absence of control over the outcome of a situation, which might contribute to depressive symptomatology. In terms of support network challenges, Brown and Harris's research has shown that mothers with dependent children who do not have a confiding relationship with a partner may be more susceptible to depression. The absence of a close, trusting relationship can leave these mothers feeling isolated, which increases their vulnerability to depression. Strained relationships, particularly in the familial or marital context, can lead to emotional distress that may trigger depression. These relationships are foundational to many people's support systems, and issues here can have far-reaching implications for mental health. In terms of psychodynamic factors, the psychodynamic approach suggests that depression can arise from conflicts between the conscious and unconscious mind. These conflicts may stem from past experiences or repressed emotions and can exert a powerful influence on an individual's psyche, potentially leading to depression. In terms of anger turned inward, according to the theory, individuals may direct feelings of anger and disappointment inward towards themselves rather than expressing these emotions outwardly. This inwardly directed anger can manifest as self-blame and feelings of worthlessness, which are common features of depression.
In terms of biological factors, depression has been associated with imbalances in neurotransmitters—the chemicals in the brain that transmit signals between neurons. Serotonin, a monoamine neurotransmitter, is particularly noted for its influence on mood, and imbalances in serotonin levels have been linked to depressive states. HPA axis deregulation: the HPA axis plays a critical role in how the body responds to stress. Dysregulation of this axis has been observed in individuals with depression, indicating that abnormal stress responses may contribute to the development and maintenance of depression. Finally, advances in brain imaging techniques, such as fMRI and PET scans, allow researchers to study the brain structure and function in living individuals. These tools have revealed differences in the brains of people with depression compared to those without, providing insights into the neurological underpinnings of the disorder and suggesting potential targets for treatment.
Evidence-based medicine (EBM) is the explicit and judicious use of current best evidence in making decisions about the care of individual patients. It integrates clinical experience with the best available research information. However, EBM can sometimes be misused when treatments are applied too broadly without considering the individual's specific circumstances. For instance, antidepressant medications, particularly SSRIs (selective serotonin reuptake inhibitors), are a cornerstone of depression treatment and are supported by EBM. They work by increasing serotonin levels in the brain, which can improve mood. While they are effective for many, they are not a one-size-fits-all solution. Cognitive behavioral therapy (CBT) is another evidence-based treatment for depression. CBT helps patients address negative patterns of thoughts and behaviors that contribute to depression. It is a structured, time-limited therapy that has a strong evidence base. However, it's crucial to consider the etiology of depression on an individual basis. For example, if marital discord is at the root of someone's depression, then the most appropriate treatment might be marital counseling or even divorce mediation, rather than medication or individual therapy. Psychosocial interventions can include casework, psychodynamic psychotherapy, marital or family therapy or mediation, group therapy, and, for some chronic patients, psychiatric rehabilitation services. These treatments are tailored to address the social and psychological factors contributing to the individual's depression.
Continuation therapy and maintenance treatment are also part of a comprehensive treatment approach. Continuation therapy is designed to prevent relapse by continuing treatments beyond the resolution of symptoms, typically for four to six months. This approach is backed by research showing that the risk of relapse is highest in the six months following recovery, and continuation therapy, especially with antidepressants, has been found effective. Maintenance therapy, on the other hand, is a long-term treatment aimed at preventing future episodes of depression. It's particularly recommended for patients with a history of recurrent depression, such as those who have experienced multiple episodes within a few years or who have had three or more episodes over their lifetime. The decision to embark on maintenance therapy is based on the individual's previous history of depression and the severity of past episodes.
Electroconvulsive therapy (ECT) is a medical treatment most commonly used for patients with severe major depression or bipolar disorder that has not responded to other treatments. It involves brief electrical stimulation of the brain while the patient is under anesthesia. ECT is one of the fastest ways to relieve symptoms in severely depressed or suicidal patients. It's also particularly effective for patients who suffer from mania or a number of other mental illnesses. Despite its efficacy, the use of ECT is generally limited to severe cases due to the potential for side effects such as memory loss. The method of ECT involves passing an electric current through the brain to induce a seizure, which is believed to produce a variety of neurochemical changes. The electric current is administered through electrodes placed on the patient's scalp. The treatment can be done bilaterally (electrodes on both sides of the head) or unilaterally (both electrodes on the same side of the head). Unilateral ECT is generally thought to cause fewer cognitive side effects than bilateral ECT. A typical course of ECT involves approximately three treatments per week for a total amount of around six to twelve treatments, although some patients may receive up to twenty treatments. The number of treatments depends on the patient's response and the severity of symptoms. ECT can be performed on an outpatient basis, but this requires that the patient's safety and post-treatment care are adequately managed. This may include ensuring that the patient does not drive immediately after treatment and that they have support at home.
In the case of psychotic depression, where the patient experiences severe depression along with delusions or hallucinations, an antipsychotic medication is usually prescribed in conjunction with other treatments, including ECT, to manage the active psychotic symptoms. It is critical to tailor the treatment to the individual's needs, considering both the potential benefits and risks.
In the short term, the response rate to antidepressants and cognitive behavioral therapy for depression is approximately 50%. It is important to note that there is a significant placebo response in depression treatment, which can be more than 20%. This suggests that some individuals may experience an improvement in their symptoms even without active medication, likely due to the expectation of help or the supportive interactions involved in treatment. Over the long term, relapse is unfortunately common, particularly when treatment is limited to pharmacological therapy alone. Ongoing medication, psychotherapy, or a combination of both is often recommended to reduce the risk of relapse.
In continuation therapy studies for depression, the research design commonly includes patients who have initially responded to an antidepressant during the acute phase of treatment. After this initial response, these patients are then randomized into two groups: one group continues to receive the antidepressant medication, while the other group is switched to a placebo. This methodology allows researchers to compare the effectiveness of ongoing antidepressant treatment against a non-treatment condition while controlling for the placebo effect. The results from such studies consistently show that continuation therapy with an antidepressant is more effective than placebo in preventing relapse. This finding underscores the importance of continued treatment following initial improvement, not just with psychomedicine but also with psychotherapy and other treatment modalities. The principle behind continuation treatment is to maintain the gains achieved during the acute treatment phase and prevent a return of depression. A review by Keller and Boland provides evidence supporting the value of continuation therapy. The review highlights that the risk of relapse is particularly high during the first six months following a patient's recovery from a depressive episode. It was found that continuation therapy with antidepressant medications significantly reduces the likelihood of relapse during this vulnerable period, emphasizing the necessity of sustained treatment. The implication here is that there is a need for ongoing treatment strategies, including psychotherapy, to maintain recovery and minimize the risk of relapse. In psychotherapy, this may involve regular sessions that decrease in frequency over time, booster sessions to reinforce skills and strategies learned during acute treatment, or step-down programs where patients move from more intensive therapy to less intensive maintenance-level care. Overall, the evidence from continuation therapy research aligns with the broader principles of chronic disease management, where sustained long-term treatment can be crucial for maintaining health and preventing exacerbation of the condition.
When it comes to evaluating the effectiveness of treatments other than antidepressants and CBT, difficulties can arise, especially with conducting randomized controlled trials. Many psychosocial interventions are complex and cannot be easily standardized across different patients, making it challenging to produce reliable estimates of response rates through RCTs. The importance of individualized treatment is highlighted by these issues. The variability in patients' backgrounds, specific symptoms, and personal circumstances necessitates a tailored approach to treatment to achieve the best outcomes. This may involve a combination of medications, various forms of psychotherapy, lifestyle changes, and support systems.
Furthermore, the risk of suicide associated with depression is a critical concern. Approximately 10% of individuals with depression may attempt suicide, and therefore monitoring for suicidal ideation or behaviors is a vital component of managing depression. Clinicians need to be vigilant, assess risk regularly, and provide appropriate interventions when necessary to ensure patient safety. This may include more intensive treatment options, hospitalization if needed, and close follow-up care.
Major depressive disorders can indeed present diagnostic challenges, especially when they share symptoms with anxiety disorders. The overlap between anxiety and depression is common, and differentiating between them often hinges on a thorough clinical assessment that considers the severity and chronology of symptoms. For example, if anxiety symptoms were prominent and occurred prior to the onset of depressive symptoms, an anxiety disorder may be more likely, and vice versa. However, many patients experience both sets of symptoms simultaneously or may transition from one to the other over time. The differential diagnosis becomes even more complex with the presence of psychotic features in depression, known as depressive psychosis. In such cases, the psychosis is typically mood-congruent, with delusions or hallucinations that are consistent with depressive themes such as personal inadequacy or guilt. This differs from other psychotic disorders. While the content of delusions and hallucinations may not be mood-congruent in schizoaffective disorder, the situation is further complicated by the presence of symptoms that are characteristic of both schizophrenia and mood disorder (either depression or bipolar disorder). The diagnosis of schizoaffective disorder is usually made when there is a significant mood component alongside the psychotic symptoms that also occur outside of mood episodes.
Cognitive impairment is another dimension that can complicate the clinical picture. Patients with severe depression can experience memory and concentration difficulties, sometimes to the extent that it resembles a dementia-like condition, often referred to as pseudodementia. However, unlike dementia, the cognitive impairment associated with depression typically improves as the mood disorder is treated and the patient's mood lifts.
In all these cases, the key to accurately diagnosing and effectively treating a person is a comprehensive clinical evaluation. This should include a detailed patient history, assessment of symptom severity, chronology, and impact on functioning, as well as the use of standardized diagnostic criteria and scales. Often, the diagnosis may need to be revisited and refined over time as new information emerges and as the patient responds to treatment. Given the complexity of these diagnostic challenges, clinicians frequently adopt a trial-and-error approach to treatment, starting with the most likely diagnosis and then adjusting treatment based on the patient's response. Continual assessment and close monitoring are essential, as is the flexibility to adjust the diagnosis and treatment plan as needed.
Thank you very much. This is the end of the session.